Secondary Offerings

2.21.2017 Secondary Announcement

SUBSCRIBE TO THE IPO BOUTIQUE NEWSLETTER   IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: GMS, Inc. Symbol: GMS Price: Last Trade $28.92 Trade Date: 2/23 Shares: 6 million[…]

02.15.2017 Secondary Announcement

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Martin Midstream Partners L.P. Symbol: MMLP Price: Last trade $18.85 Description: Re-offer range $18.00-$18.25 Trade Date: 2/16 Shares: 2.6 million Underwriter(s)RBC[…]

02.14.2017 Secondary Announcement

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Seacoast Banking Corporation Symbol: SBCF Price: Last trade $23.97 Description: No re-offer range available Trade Date: 2/15 Shares: 4.2 million Underwriter(s)Guggenheim[…]

02.13.2017 Secondary Announcement

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Aldeyra Therapeutics Inc. Symbol: ALDX Price: Last trade $4.75 Description: Re-offer $4.50 Trade Date: 2/14 Shares: 2.2 million Underwriter(s)Stifel, Canaccord Genuity,[…]

02.09.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: BioTime Symbol: BTX Price: Last trade $3.01 Description: Re-offer $2.70-$2.75 Trade Date: 2/10 Shares: 5.7 million Underwriter(s)Raymond James & Associates Rating=Subscription[…]

02.08.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Sierra Oncology Symbol: SRRA Price: Last trade $1.42 Description: Re-offer $1.35 Trade Date: 2/9 Shares: 18.5 million Underwriter(s)Jefferies Rating=Subscription Needed

02.07.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Coherus Biosciences Symbol: CHRS Price: Last trade $26.65 Description: Re-offer range $24.00-$25.00 Trade Date: 2/8 Shares: 4.7 million Underwriter(s)J.P. Morgan, Citigroup,[…]

2.06.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Antero Midstream Partners LP Symbol: AM Price: Last trade $33.89 Description: Re-offer range $33.20-$33.55 Trade Date: 2/7 Shares: 5 million Underwriter(s)Barclays,[…]

2.2.2017 Secondary announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Neos Therapeutics Symbol: NEOS Price: Last trade $5.80 Description: Re-offer $5.00 Trade Date: 2/3 Shares: 5 million Underwriter(s)Cowen & Co., BMO[…]

02.01.2017 Secondary Announcement-p.m.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Smart Sand *amendment since this a.m. announcement Symbol: SND Price: Last Trade $17.40 Trade Date: 2/2 Shares: 5 million **increased from[…]

IPO Boutique announces a Secondary (2.1.17am)

SUBSCRIBE TO IPOBoutique’s Free Weekly Newsletter  Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.  For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a[…]

01.31.17 Secondary Announcement-P.M.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Synergy Pharmaceuticals, Inc. Symbol: SGYP Price: Last trade $7.07 Description: Re-offer range $6.60-$6.85 Trade Date: 2/1 Shares: 17.7 million Underwriter(s)Cantor Fitzgerald,[…]

1/30/17 Secondary Announcement-P.M.

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Rigel Pharmaceuticals Symbol: RIGL Price: Last trade $2.08 Description: Re-offer $2.00 Trade Date: 1/31 Shares: 17.5 million Underwriter(s)Jefferies, Piper Jaffray, BMO[…]

Secondaries Announced 1.30.17am

SUBSCRIBE TO IPOBoutique’s Free Weekly Newsletter    Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is[…]

Secondaries announced 01.26.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Workhorse Symbol: WKHS Price: Last trade $3.47 Description: Re-offer $3.00 Trade Date: 1/27 Shares: 4.3 million Underwriter(s)Oppenheimer & Co., Cowen &[…]

Secondaries announced 01.25.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Entellus Medical, Inc. Symbol: ENTL Price: Last trade $19.39 Description: Re-offer range $17.00-$18.00 Trade Date: 1/26 Shares: 3.1 million Underwriter(s)BofA Merrill[…]

Secondaries announced 01.24.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Horizon Global Corporation Symbol: HZN Price: Last trade $20.89 Trade Date: 1/27 Shares: 3.5 million Underwriter(s)Wells Fargo, J.P. Morgan, BofA Merrill[…]

IPO Boutique announces a secondary (1.24.17)

SUBSCRIBE TO IPOBoutique’s Free Weekly Newsletter   Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is[…]

Secondaries announced 01.23.2017

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Pinnacle Financial Partners, Inc. Symbol: PNFP Price: Last trade $64.25 Description: Re-offer range $61.25-$63.25 Trade Date: 1/24 Shares: 2.7 million Underwriter(s)J.P.[…]

Secondaries Announced 1.23.17 AM

SUBSCRIBE TO IPOBoutique’s Free Weekly Newsletter   Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is[…]

Scroll to top
error: Content is protected !!